Puma Biotechnology(US:PBYI) ZACKS·2025-11-07 16:56Core Insights - Puma Biotechnology reported third-quarter 2025 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 9 cents, but down from 45 cents in the same quarter last year [2][7] - Total revenues for the third quarter were $54.5 million, surpassing the Zacks Consensus Estimate of $48 million, but reflecting a 32.3% year-over-year decline due to reduced product supply revenues and higher gross-to-net reductions [3][7] - The company raised its 2025 revenue guidance to $220-$223 million, up from the previous range of $212-$222 million, indicating a positive outlook for Nerlynx product sales [10][11] Financial Performance - Product revenues from Nerlynx totaled $51.9 million in Q3, a decrease of 7.5% year over year, yet above management's guidance of $46-$48 million [5][7] - Royalty revenues were $2.6 million, significantly down from $24.4 million in the prior year, but exceeded the model estimate of $2.2 million [8] - Total operating costs for the quarter were $44.9 million, down 23.1% year over year, while research and development expenses rose 27.2% to $15.9 million [8][9] Market Performance - Shares of Puma Biotechnology have increased by 60.7% year to date, outperforming the industry average rise of 11.5% [4] Guidance and Future Outlook - For Q4 2025, total revenues are expected to be between $67-$70 million, with Nerlynx product sales projected at $54-$56 million and royalty revenues anticipated in the range of $13-$14 million [11] - The company is also developing alisertib for various cancers, with interim data from ongoing studies expected in the first half of 2026 [12][13][14]